← board
PRQR
distress 2/10 · well-funded / low risk$1.80-1%today-41% from 52w high
Revenue
pre-revenue
Liquidity
$81M
Runway
1.5 yrs
Shares 1y
0%
Price & events
+5.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
+7.8%
1W
-4.8%
1M
+10.4%
3M
+2.9%
6M
-17.1%
1Y
-4.5%
2Y
-67.2%
5Y
-56.5%
All
Overview
- Market Cap
- $189.65M
- Volume
- 47.66K
- 52 Week Range
- $1.37 – $3.05
- Total Shares
- 105.36M
- Float Shares
- 78.96M
- Short %
- 1.12%
- % Held by Insiders
- 14.22%
- % Held by Institutions
- 38.63%
- RVOL
- 0.03x
- Beta
- 0.03
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $8 (+358% upside) · 8 analysts
- 2026-06-29Evercore ISI GroupOutperform
- 2026-06-26Chardan CapitalBuy
- 2026-06-26Jones TradingBuy
- 2026-04-09Chardan CapitalBuy
- 2025-11-04Chardan CapitalBuy
- 2025-08-08Chardan CapitalBuy
Competitors
- none identified
Recent news
- 2026-07-22Privium Fund Management B.V. Increases Stake in ProQR Therapeuti - GuruFocus
- 2026-07-21Bart Filius Acquires Additional Shares in ProQR Therapeutics NV - GuruFocus
- 2026-07-21Form 4 ProQR Therapeutics N.V. For: 21 July By Investing.com - Investing.com South Africa
- 2026-07-21Form 4 ProQR Therapeutics N.V. For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21Proqr Therapeutics N.v. Insider Bought Shares Worth $257,925, According to a Recent SEC Filing - marketscreener.com
- 2026-07-21ProQR Therapeutics (PRQR) director purchases 150,000 Ordinary Shares - Stock Titan
- 2026-07-21ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving Average - Here's Why - MarketBeat
- 2026-07-21ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.